Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.41)
# 4,268
Out of 5,140 analysts
16
Total ratings
28.57%
Success rate
-19.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.40 | +655.67% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.75 | +814.29% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $3.25 | +176.92% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $4.03 | +98.51% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $31.47 | +217.76% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.51 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.22 | +68,897.24% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $1.32 | +1,036.36% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $3.14 | +568.79% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $70.39 | +27.86% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.59 | +11,869.11% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $2.08 | +1,615,284.62% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.40
Upside: +655.67%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.75
Upside: +814.29%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $3.25
Upside: +176.92%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $4.03
Upside: +98.51%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $31.47
Upside: +217.76%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.51
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.22
Upside: +68,897.24%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $1.32
Upside: +1,036.36%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $3.14
Upside: +568.79%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $70.39
Upside: +27.86%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.59
Upside: +11,869.11%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $2.08
Upside: +1,615,284.62%